The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2;COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries
Michael C. Grant,Luke Geoghegan,Marc Arbyn,Zakaria Mohammed,Zakaria Mohammed,Luke A McGuinness,Emily L. Clarke,Ryckie G. Wade,Ryckie G. Wade +8 more
Reads0
Chats0
TLDR
It is confirmed that fever and cough are the most prevalent symptoms of adults infected by SARS-CoV-2, however, there is a large proportion of infected adults which symptoms-alone do not identify.Abstract:
Background To limit the spread of SARS-CoV-2, an evidence-based understanding of the symptoms is critical to inform guidelines for quarantining and testing. The most common features are purported to be fever and a new persistent cough, although the global prevalence of these symptoms remains unclear. The aim of this systematic review is to determine the prevalence of symptoms associated with COVID-19 worldwide. Methods We searched PubMed, Embase, CINAHL, AMED, medRxiv and bioRxiv on 5th April 2020 for studies of adults (>16 years) with laboratory test confirmed COVID-19. No language or publication status restrictions were applied. Data were independently extracted by two review authors into standardised forms. All datapoints were independently checked by three other review authors. A random-effects model for pooling of binomial data was applied to estimate the prevalence of symptoms, subgrouping estimates by country. I2 was used to assess inter-study heterogeneity. Results Of 851 unique citations, 148 articles were included which comprised 24,410 adults with confirmed COVID-19 from 9 countries. The most prevalent symptoms were fever (78% [95% CI 75%-81%]; 138 studies, 21,701 patients; I2 94%), a cough (57% [95% CI 54%-60%]; 138 studies, 21,682 patients; I2 94%) and fatigue (31% [95% CI 27%-35%]; 78 studies, 13,385 patients; I2 95%). Overall, 19% of hospitalised patients required non-invasive ventilation (44 studies, 6,513 patients), 17% required intensive care (33 studies, 7504 patients), 9% required invasive ventilation (45 studies, 6933 patients) and 2% required extra-corporeal membrane oxygenation (12 studies, 1,486 patients). The mortality rate was 7% (73 studies, 10,402 patients). Conclusions We confirm that fever and cough are the most prevalent symptoms of adults infected by SARS-CoV-2. However, there is a large proportion of infected adults which symptoms-alone do not identify.read more
Citations
More filters
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Posted Content
COVID-19 Generated Changes to Planning and Development Controls in South Australia (preprint)
TL;DR: Nearly 50% COVID-19 patients could not reach obvious clinical and radiological remission within 10 days after hospitalization, and the patients with male sex, anorexia and no fever on admission predicted poor efficacy.
Journal ArticleDOI
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Richard R. Orlandi,Todd T. Kingdom,Timothy L. Smith,Benjamin S. Bleier,Adam S. DeConde,Amber U Luong,David M. Poetker,Zachary M. Soler,Kevin C. Welch,Sarah K. Wise,Nithin D. Adappa,Jeremiah A. Alt,Wilma Terezinha Anselmo-Lima,Claus Bachert,Claus Bachert,Claus Bachert,Fuad M. Baroody,Pete S. Batra,Manuel Bernal-Sprekelsen,Daniel M. Beswick,Neil Bhattacharyya,Rakesh K. Chandra,Eugene H. Chang,Alexander G. Chiu,Naweed I. Chowdhury,Martin J. Citardi,Noam A. Cohen,David B. Conley,John M. DelGaudio,Martin Desrosiers,Richard G. Douglas,Jean Anderson Eloy,Wytske Fokkens,Stacey T. Gray,David A. Gudis,Daniel L. Hamilos,Joseph K. Han,Richard J. Harvey,Peter Hellings,Eric H. Holbrook,Claire Hopkins,Peter H. Hwang,Amin R. Javer,Rong San Jiang,David N. Kennedy,Robert C. Kern,Tanya M. Laidlaw,Devyani Lal,Andrew P. Lane,Heung Man Lee,Jivianne T. Lee,Joshua M. Levy,Sandra Y. Lin,Valerie J. Lund,Kevin C. McMains,Ralph Metson,Joaquim Mullol,Robert M. Naclerio,Gretchen M. Oakley,Nobuyoshi Otori,James N. Palmer,Sanjay R. Parikh,Desiderio Passali,Zara M. Patel,Anju T. Peters,Carl Philpott,Alkis J. Psaltis,Vijay R. Ramakrishnan,Murugappan Ramanathan,Hwan Jung Roh,Luke Rudmik,Raymond Sacks,Rodney J. Schlosser,Ahmad R. Sedaghat,Brent A. Senior,Raj Sindwani,Kristine A. Smith,Kornkiat Snidvongs,Michael G. Stewart,Jeffrey D. Suh,Bruce K. Tan,Justin H. Turner,Cornelis M. van Drunen,Richard Louis Voegels,De Yun Wang,Bradford A. Woodworth,Peter-John Wormald,Erin D. Wright,Carol H. Yan,Luo Zhang,Bing Zhou +90 more
TL;DR: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in the understanding and treatment of rhinologic disease.
Journal ArticleDOI
Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh.
Reaz Mahmud,Mujibur Rahman,Mohammad Aftab Rassel,Farhana Binte Monayem,S. K. Jakaria Been Sayeed,Shahidul Islam,Mohammed Monirul Islam +6 more
TL;DR: In this paper, the authors conducted a prospective cohort study to determine the incidence, association, and risk factors associated with development of the post-coronavirus disease (COVID-19) syndrome.
Journal ArticleDOI
Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection.
TL;DR: Current evidence is critically examined whether and how the SARS-CoV-2 virus can follow a route from the olfactory epithelium in the nose to the brain to achieve brain infection and the prospects for using the smell and taste dysfunctions seen in COVID-19 as an early and rapid diagnostic screening tool are discussed.
References
More filters
Posted ContentDOI
Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support
Giuseppe Gritti,Federico Raimondi,Diego Ripamonti,Ivano Riva,Francesco Landi,Leonardo Alborghetti,Marco Frigeni,Marianna Damiani,Caterina Micò,Stefano Fagiuoli,Roberto Cosentini,Ferdinando Luca Lorini,Lucia Gandini,Luca Novelli,Jonathan P Morgan,Benjamin M. J. Owens,Karan J K Kanhai,Gordana Tonkovic Reljanovic,Marco Rizzi,Fabiano Di Marco,Alessandro Rambaldi +20 more
TL;DR: Preliminary data are presented to inform the medical community of the potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection, and a cohort study with patients treated with standard therapy in this hospital is ongoing, and will report the 30-day mortality rates upon completion.
Journal ArticleDOI
Clinical Characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China
Jiaojiao Chu,Nan Yang,Yanqiu Wei,Huihui Yue,Fengqin Zhang,Jianping Zhao,Li He,Gaohong Sheng,Peng Chen,Gang Li,Si-Si Wu,Bo Zhang,Shu Zhang,Cong-Yi Wang,Xiaoping Miao,Juan Li,Wenhua Liu,Huilan Zhang +17 more
TL;DR: Training for all hospital staff to prevent infection and preparation of sufficient protection and disinfection materials are suggested for medical staff infection data.
Journal ArticleDOI
Duration and quality of the peer review process: the author's perspective.
Janine Huisman,Jeroen Smits +1 more
TL;DR: Qualitative information provided by the authors indicates that editors can enhance author satisfaction by taking an independent position vis-à-vis reviewers and by communicating well with authors.
Posted ContentDOI
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
Huijie Bian,Zhaohui Zheng,Ding Wei,Zheng Zhang,Wenzhen Kang,Chunqiu Hao,Ke Dong,Wen Kang,Jie-Lai Xia,Jinlin Miao,Ronghua Xie,Bin Wang,Xiu-Xuan Sun,Xiang-Min Yang,Peng Lin,Jie-Jie Geng,Ke Wang,Hong-Yong Cui,Kui Zhang,Xiaochun Chen,Hao Tang,Hong Du,Na Yao,Shuangshuang Liu,Lin-Na Liu,Zhe Zhang,Zhao-wei Gao,Gang Nan,Qing-Yi Wang,Jian-Qi Lian,Zhi-Nan Chen,Ping Zhu +31 more
TL;DR: Assessment of the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia found it efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile.
Posted ContentDOI
COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province,China
Qingxian Cai,Deliang Huang,Pengcheng Ou,Hong Yu,Zhibin Zhu,Zhang Xia,Yinan Su,Zhenghua Ma,Yiming Zhang,Zhiwei Li,Qing He,Yang Fu,Lei Liu,Jun Chen +13 more
TL;DR: In a designated hospital outside the Hubei Province, COVID-19 patients were mainly characterized by mild symptoms and could be effectively manage by properly using the existing hospital system.
Related Papers (5)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu,Jennifer M. McGoogan +1 more